Key facts
- This page summarizes Christopher I. Wright's Form 4 filing for Alkermes plc. (ALKS).
- 8 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 04 Jun 2024, 17:05.
Christopher I. Wright - 31 May 2024 Form 4 Insider Report for Alkermes plc. (ALKS)
- Reporting relationship
- Director
- Issuer ticker
- ALKS
- Reported as of
- 31 May 2024
- Net transaction value
- +$25,411
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 17:05:16 UTC
- Prior SEC filing
- 10 Jul 2023
- Next SEC filing
- 10 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shantale Greenson, attorney-in-fact for Christopher I. Wright
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher I. Wright filed Form 4 for Alkermes plc. (ALKS) on 04 Jun 2024.
Change
- Previous filing in this sequence was filed on 10 Jul 2023.
- Current net transaction value: +$25,411.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALKS
transaction
Derivative
Non Qualified Stock Option (Right to Buy)
Other
- Transaction value
- $398
- Shares
- +14
- Change %
- +2%
- Price
- $28.40
- Shares after
- 728
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 14
- Exercise price
- $28.40
- Footnotes
- F1, F2
ALKS
transaction
Derivative
Non Qualified Stock Option (Right to Buy)
Other
- Transaction value
- $10,082
- Shares
- +355
- Change %
- +2%
- Price
- $28.40
- Shares after
- 18,128
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 355
- Exercise price
- $28.40
- Footnotes
- F1, F3
ALKS
transaction
Derivative
Restricted Stock Unit Award
Other
- Transaction value
- Shares
- +129
- Change %
- +2%
- Price
- Shares after
- 6,602
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 129
- Exercise price
- Footnotes
- F1, F4, F5
ALKS
transaction
Derivative
Non Qualified Stock Option (Right to Buy)
Other
- Transaction value
- $7,129
- Shares
- +231
- Change %
- +2%
- Price
- $30.86
- Shares after
- 11,785
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 231
- Exercise price
- $30.86
- Footnotes
- F1, F2
ALKS
transaction
Derivative
Non Qualified Stock Option (Right to Buy)
Other
- Transaction value
- $7,803
- Shares
- +254
- Change %
- +2%
- Price
- $30.72
- Shares after
- 12,986
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 254
- Exercise price
- $30.72
- Footnotes
- F1, F6
ALKS
transaction
Derivative
Restricted Stock Unit Award
Other
- Transaction value
- Shares
- +119
- Change %
- +2%
- Price
- Shares after
- 6,104
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 119
- Exercise price
- Footnotes
- F1, F4, F7
ALKS
transaction
Derivative
Restricted Stock Unit Award
Award
- Transaction value
- $0
- Shares
- +8,013
- Change %
- Price
- $0.000000
- Shares after
- 8,013
- Date
- 31 May 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 8,013
- Exercise price
- Footnotes
- F4, F8
ALKS
transaction
Derivative
Non Qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +17,492
- Change %
- Price
- $0.000000
- Shares after
- 17,492
- Date
- 31 May 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 17,492
- Exercise price
- $23.40
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
Footnote F2
These options are fully vested in accordance with their terms.
Footnote F3
Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.
Footnote F4
Each restricted stock unit represents a contingent right to receive one ordinary share.
Footnote F5
Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.
Footnote F6
Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
Footnote F7
Shares subject to the restricted stock unit award vest in full on 6/29/2024.
Footnote F8
Shares subject to the restricted stock unit award vest in full on 5/31/2025.
Footnote F9
Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.
SEC remarks
EXHIBIT LIST: Exhibit 24.1 - Power of Attorney